Vomiting fell to 43% of patients on tradipitant versus 58.5% on placebo. Vanda plans to seek an expanded approval for GLP-1-induced vomiting.
Recap by typeshit. Full story at MPR.
Half of people with diabetes for 10 years or more said they were very satisfied on a GLP-1. Gen Z users were the most likely to stop and restart treatment.
64% of current users faced some negative reaction. Men, BIPOC respondents and the newly diagnosed reported it most, while 69% of boomers felt none.
The workflow uses glutathione or sulfatase triggers to target organelles and tumors in mice, and the authors say it takes 92 to 115 days to run.
A University of Pennsylvania mouse study found on-off GLP-1 use left mice 20 per cent heavier than those kept on the drug, and doctors warn human effects are unknown.
Drugs.com
A UC San Diego trial of 166 teens found 22% held their loss a year later with mood training, versus 4% with standard counseling. No drugs involved.
Lynette Ntuli posts about a risk she says doctors flag for type 2 diabetics taking Ozempic. The text is cut off, so see her full post for details.
Loading…